Novel Treatment Approach May Reduce Risk of Death From ICI-Related Myocarditis
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
A novel method of treating immune checkpoint inhibitor-associated myocarditis may decrease the risk of death from myotoxicity.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Most prominent increase seen for spouses of patients diagnosed with cancer with poor prognosis, at advanced stage.
Researchers sought to determine whether survivors of gynecologic cancers had a higher risk of sexual dysfunction, compared with cancer-free women, and the risk factors for sexual dysfunction.
A randomized trial sought to determine whether prone position for adjuvant radiotherapy to the breast results in less skin toxicity in women with large breasts.
A survey of men with prostate cancer sought to identify when these patients were most vulnerable to symptoms of depression and/or anxiety.
A substudy of a pilot yoga intervention may have identified a biomarker for CIPN in patients with cancer treated with neurotoxic chemotherapy.
A retrospective, observational study sought to identify prognostic factors for cardiovascular immune-related adverse events in patients with NSCLC treated with immune checkpoint inhibitors.
Analysis of patient-reported questionnaire results showed predictors of recovery for patients undergoing allo-HSCT.
Researchers described dermatologic events associated with the use of enfortumab vedotin in treatment of locally advanced/metastatic urothelial cancer.